Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Pelago and AstraZeneca enter CETSA research collaboration

Posted: 27 November 2015 | | No comments yet

Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas…

Pelago Bioscience and AstraZeneca have entered into a 2-year strategic research collaboration and license agreement on the Cellular Thermal Shirt Assay (CETSA) method.

The companies will collaborate on specified joint projects and AstraZeneca will also be granted a license to use and apply CETSA for determination and quantification of drug–target interactions in other AstraZeneca discovery projects.

During the collaboration Pelago and AstraZeneca will together develop assay formats and applications of the CETSA method relevant across the range of AstraZeneca’s therapeutic areas. The companies will actively share information related to benchmarking and improvement in the use of the technology.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

CETSA will allow AstraZeneca to examine the interaction between candidates and targets

“We are very proud of this collaborative agreement with AstraZeneca. It will allow us to further improve the CETSA method using the knowledge and experience from one of the world’s largest drug discovery companies,” says Michael Dabrowski CEO of Pelago Bioscience.

Mike Snowden, Vice President Discovery Sciences AstraZeneca said: “CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell. We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”

Related topics
,

Related organisations